Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ANTIVIRAL AGENTS FOR THE PREVENTION AND TREATMENT ON INFLUENZA Preventing and reducing the impact of influenza • Good personal hygiene: good etiquette when coughing and sneezing, hand washing • Protecting others by reducing exposure: staying at home when ill, reducing workplace contact, etc. • Annual vaccination • Antiviral agents for prevention and treatment Antivirals for influenza: Principles of use • Vaccination is the primary method for the prevention of influenza • Antivirals are useful for treatment of influenza and as a secondary means of preventing influenza • Antivirals should be used where they have the greatest benefit • Antivirals should be used responsibly in order to minimise the risk of emergence of drug resistance • It is important that there is adequate availability of antivirals when required, including stockpiling for pandemic use Influenza surface proteins Neuraminidase Hemagglutinin RNA M2 protein (only on type A) Antiviral agents for influenza: two classes of drugs • Matrix protein (M2) inhibitors – amantadine and rimantadine – inhibit virus coating – influenza A only • Neuraminidase inhibitors – oseltamivir and zanamivir – inhibit release of virus from infected cells – active against all known strains of influenza Antiviral agents for influenza Class Drug M2 Inhibitors Amantadine Oral Rimantadine Oral Neuraminidase Inhibitors Zanamivir Oseltamivir Administration Inhaled Oral Antiviral drugs for influenza • They may be used to treat influenza but they should be given within 48 hours of developing symptoms. • They act by decreasing the severity of illness and decreasing the duration of illness. • An adjunct to influenza vaccine for controlling and preventing influenza but not a substitute for vaccination. • Not effective in preventing or treating serious influenza-related complications (e.g. bacterial or viral pneumonia or exacerbation of chronic diseases). M2 inhibitors: Mechanism Neuraminidase Hemagglutinin RNA H+ H+ H+ H+ X M2 inhibitors M2 protein (only on type A) • M2 channel allows acidification of virus • Initiates uncoating of viral RNA • Allows viral replication • M2 inhibitors block this action By courtesy of APACI Asia-Pacific Advisory Committee on influenza www.apaci-flu.com